<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02995746</url>
  </required_header>
  <id_info>
    <org_study_id>15-475</org_study_id>
    <nct_id>NCT02995746</nct_id>
  </id_info>
  <brief_title>Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane</brief_title>
  <acronym>DEMO</acronym>
  <official_title>Intravitreal Dexamethasone Implant for Persistent Macular Thickening and Edema After Vitrectomy for Epiretinal Membrane: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mid Atlantic Retina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wills Eye</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study seeks to evaluate the effect of the intravitreal 0.7mg dexamethasone implant on&#xD;
      central macular thickness and visual acuity in those patients with persistent macular edema&#xD;
      after pars plana vitrectomy for epiretinal membrane.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Macular edema is a relatively common occurrence after pars plana vitrectomy. Kim et al&#xD;
      described that 47% of eyes undergoing vitrectomy for epiretinal membrane, macular hole, or&#xD;
      vitreous hemorrhage had evidence of macular thickening on optical coherence tomography scan.1&#xD;
      Post-vitrectomy macular edema can limit potential visual acuity gain from removal of a&#xD;
      symptomatic epiretinal membrane. Typical treatment of post-operative macular edema consists&#xD;
      of topical non-steroidal anti-inflammatory drugs (NSAIDs) and topical corticosteroids;&#xD;
      however, there are still resistant cases with refractory macular thickening.&#xD;
&#xD;
      The dexamethasone intravitreal implant (Ozurdex; Allergan, Irvine, CA) is currently&#xD;
      FDA-approved for the treatment of posterior uveitis as well as macular edema secondary to&#xD;
      retinal vein occlusion and diabetic retinopathy. Furino et al reported a retrospective series&#xD;
      describing how a single injection of the 0.7mg dexamethasone intravitreal implant resulted in&#xD;
      a substantial increase in best-corrected visual acuity (BCVA) and a decrease in central&#xD;
      macular thickness (CMT) on spectral-domain optical coherence tomography (SD-OCT) in 8&#xD;
      patients with persistent macular thickening after pars plana vitrectomy for epiretinal&#xD;
      membrane. There has been no prospective study evaluating the efficacy of this pharmacologic&#xD;
      agent in this setting.&#xD;
&#xD;
      As such, the purpose of this study is to prospectively evaluate the effect of the&#xD;
      intravitreal 0.7mg dexamethasone implant on CMT and BCVA in those patients with persistent&#xD;
      macular edema after pars plana vitrectomy for epiretinal membrane.&#xD;
&#xD;
      The results of this study will help delineate whether the intravitreal dexamethasone implant&#xD;
      has efficacy in improving CMT and/or visual acuity in those patients with refractory macular&#xD;
      thickening after pars plana vitrectomy for epiretinal membrane.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated due to lack of drug efficacy. 2017 study did not show benefit.&#xD;
  </why_stopped>
  <start_date type="Actual">January 28, 2016</start_date>
  <completion_date type="Actual">September 14, 2017</completion_date>
  <primary_completion_date type="Actual">September 14, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean central macular thickness (CMT) on SD-OCT at 1 month, 3 months, and 6 months after intravitreal injection of dexamethasone implant</measure>
    <time_frame>Change in mean macular thickness baseline at 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>Change in visual acuity baseline at 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Macular Edema</condition>
  <condition>Epiretinal Membrane</condition>
  <condition>Vitrectomy</condition>
  <arm_group>
    <arm_group_label>0.7mg dexamethasone intravitreal implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravitreal implantation of 0.7mg dexamethasone with a six month follow up period</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>On study visit #1 all patients will have a SD-OCT scan and measurement of baseline visual acuity. All patients will receive the 0.7mg dexamethasone intravitreal implant&#xD;
Subsequent follow-up visits will be at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months after intravitreal injection of dexamethasone implant&#xD;
Each visit will consist of measurement of visual acuity, intraocular pressure, dilated fundoscopic examination, and SD-OCT scan&#xD;
Anticipated duration of the study: 6 months</description>
    <arm_group_label>0.7mg dexamethasone intravitreal implant</arm_group_label>
    <other_name>Ozurdex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient of the Wills Eye Institute Retina service, including all Mid-Atlantic Retina&#xD;
             offices&#xD;
&#xD;
          2. Volunteer patients age 18 years and older&#xD;
&#xD;
          3. Healthy enough to participate in the study&#xD;
&#xD;
          4. Willing and able to consent to participation in the study&#xD;
&#xD;
          5. History of pars plan vitrectomy for symptomatic epiretinal membrane at least 3 months&#xD;
             prior to study enrollment date&#xD;
&#xD;
          6. BCVA of 20/40 or worse&#xD;
&#xD;
          7. CMT of at least 400 micrometers with or without cystoid macular edema on SD-OCT&#xD;
&#xD;
          8. Prior treatment with topical NSAIDs without resolution of macular thickening or visual&#xD;
             acuity improvement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Advanced glaucoma (cup-disc ratio of 0.8 or greater)&#xD;
&#xD;
          2. History of glaucoma filtering or tube shunt implant surgery&#xD;
&#xD;
          3. Steroid responsive intraocular hypertension&#xD;
&#xD;
          4. Diabetic retinopathy&#xD;
&#xD;
          5. History of uveitis&#xD;
&#xD;
          6. Use of systemic or intraocular corticosteroids&#xD;
&#xD;
          7. Active or suspected ocular or periocular infections&#xD;
&#xD;
          8. Other confounding intraocular pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Allen C Ho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mid Atlantic Retina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mid Atlantic Retina</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 14, 2016</study_first_submitted>
  <study_first_submitted_qc>December 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2016</study_first_posted>
  <last_update_submitted>October 1, 2018</last_update_submitted>
  <last_update_submitted_qc>October 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Wills Eye</investigator_affiliation>
    <investigator_full_name>Allen C. Ho, MD</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Epiretinal Membrane</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>January 15, 2019</submitted>
    <returned>February 6, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

